PTC Therapeutics Ownership
| PTCT Stock | USD 56.63 0.35 0.61% |
Shares in Circulation | First Issued 2012-03-31 | Previous Quarter 76.9 M | Current Value 76.8 M | Avarage Shares Outstanding 49.8 M | Quarterly Volatility 19.9 M |
PTC |
PTC Stock Ownership Analysis
About 100.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.81. PTC Therapeutics recorded a loss per share of 4.73. The entity had not issued any dividends in recent years. PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Ptc Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people. To find out more about PTC Therapeutics contact Stuart Peltz at 908 222 7000 or learn more at https://www.ptcbio.com.Besides selling stocks to institutional investors, PTC Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different PTC Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align PTC Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
PTC Therapeutics Quarterly Liabilities And Stockholders Equity |
|
PTC Therapeutics Insider Trades History
Roughly 2.0% of PTC Therapeutics are currently held by insiders. Unlike PTC Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against PTC Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of PTC Therapeutics' insider trades
PTC Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as PTC Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PTC Therapeutics backward and forwards among themselves. PTC Therapeutics' institutional investor refers to the entity that pools money to purchase PTC Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | D. E. Shaw & Co Lp | 2024-12-31 | 1.5 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.4 M | Franklin Resources Inc | 2024-12-31 | 1.3 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.1 M | Ubs Group Ag | 2024-12-31 | 1.1 M | Blackstone Inc | 2024-12-31 | 1.1 M | Driehaus Capital Management Llc | 2024-12-31 | 1 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 826.5 K | Vanguard Group Inc | 2024-12-31 | 9.2 M | Blackrock Inc | 2024-12-31 | 7.9 M |
PTC Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PTC Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on PTC Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PTC Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
PTC Therapeutics Outstanding Bonds
PTC Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PTC Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PTC bonds can be classified according to their maturity, which is the date when PTC Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PSI ENERGY INC Corp BondUS693627AY70 | View | |
| US693656AC47 Corp BondUS693656AC47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
PTC Therapeutics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.